Profile data is unavailable for this security.
About the company
Neurocrine Biosciences, Inc. is a neuroscience-focused, biopharmaceutical company. The Company is engaged in discovering and developing treatments for patients with under-addressed neurological, neuroendocrine and neuropsychiatric disorders. Its diverse portfolio includes the United States Food and Drug Administration-approved treatments for tardive dyskinesia, chorea associated with Huntington’s disease, endometriosis and uterine fibroids, as well as a robust pipeline, including multiple compounds in mid-to late-phase clinical development across its core therapeutic areas. Its commercial products include INGREZZA, ALKINDI, EFMODY, Orilissa, and Oriahnn. INGREZZA is marketed as DYSVAL (valbenazine) in Japan and REMLEAS (valbenazine) in other select Asian markets, where Mitsubishi Tanabe Pharma Corporation retains commercialization rights. ALKINDI is marketed as ALKINDI SPRINKLE (hydrocortisone) in the United States, where Eton Pharmaceuticals, Inc. retains commercialization rights.
- Revenue in USD (TTM)2.86bn
- Net income in USD478.60m
- Incorporated1996
- Employees2.00k
- LocationNeurocrine Biosciences Inc6027 EDGEWOOD BEND COURTSAN DIEGO 92130United StatesUSA
- Phone+1 (858) 617-7600
- Fax+1 (858) 617-7602
- Websitehttps://www.neurocrine.com/
Peer analysis
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Krystal Biotech Inc | 389.13m | 204.83m | 7.71bn | 295.00 | 38.56 | 6.31 | 36.62 | 19.82 | 6.84 | 6.84 | 13.00 | 41.78 | 0.3257 | 0.6882 | 3.35 | 1,319,085.00 | 17.14 | 2.46 | 18.75 | 2.63 | 94.08 | -- | 52.64 | 13.06 | 9.56 | -- | 0.00 | 0.00 | 33.94 | -- | 129.74 | -- | -4.24 | -- |
| Halozyme Therapeutics, Inc. | 1.40bn | 316.89m | 8.19bn | 423.00 | 27.85 | 167.45 | 20.22 | 5.86 | 2.49 | 2.49 | 11.38 | 0.4144 | 0.6087 | 1.44 | 3.73 | 3,301,681.00 | 13.81 | 19.86 | 14.83 | 21.98 | 83.62 | 81.56 | 22.69 | 37.92 | 3.66 | -- | 0.9777 | 0.00 | 37.55 | 39.16 | -28.64 | 19.68 | 159.51 | -- |
| Axsome Therapeutics Inc | 638.50m | -183.17m | 8.39bn | 925.00 | -- | 94.54 | -- | 13.14 | -3.69 | -3.69 | 12.84 | 1.74 | 1.01 | 2.17 | 3.48 | 690,265.90 | -29.11 | -51.00 | -56.42 | -77.57 | 92.56 | -- | -28.69 | -76.38 | 1.48 | -25.78 | 0.6878 | -- | 65.55 | -- | 36.22 | -- | 59.92 | -- |
| Biomarin Pharmaceutical Inc | 3.22bn | 348.90m | 11.26bn | 3.22k | 32.85 | 1.85 | 26.27 | 3.49 | 1.78 | 1.78 | 16.57 | 31.65 | 0.4418 | 0.4726 | 4.11 | 1,000,079.00 | 4.79 | 3.09 | 5.28 | 3.46 | 81.43 | 78.42 | 10.83 | 8.18 | 3.50 | -- | 0.0893 | 0.00 | 12.87 | 11.60 | -18.26 | 138.08 | -4.20 | -- |
| Jazz Pharmaceuticals PLC | 4.16bn | -368.48m | 11.49bn | 2.80k | -- | 2.86 | 36.16 | 2.76 | -6.07 | -6.07 | 67.81 | 65.18 | 0.3522 | 0.936 | 5.59 | 1,484,940.00 | -3.12 | 1.36 | -3.62 | 1.50 | 88.49 | 88.18 | -8.85 | 3.98 | 1.44 | 2.17 | 0.5752 | 0.00 | 6.12 | 13.48 | 35.02 | 1.37 | -23.40 | -- |
| Elanco Animal Health Inc | 4.72bn | -232.00m | 12.37bn | 9.40k | -- | 1.89 | 27.61 | 2.62 | -0.4848 | -0.4848 | 9.53 | 13.17 | 0.3631 | 1.28 | 5.62 | 501,595.80 | -1.79 | -2.26 | -2.01 | -2.53 | 54.99 | 55.59 | -4.92 | -7.41 | 1.08 | 1.15 | 0.3803 | -- | 6.22 | 7.59 | -168.64 | -- | -2.35 | -- |
| BridgeBio Pharma Inc | 502.08m | -724.93m | 12.51bn | 834.00 | -- | -- | -- | 24.92 | -3.78 | -3.78 | 2.62 | -10.71 | 0.5412 | -- | 6.97 | 602,009.60 | -79.01 | -76.52 | -105.26 | -96.54 | 95.82 | 96.16 | -145.98 | -340.73 | 2.68 | -2.17 | 4.29 | -- | 126.26 | 127.44 | -35.31 | -- | 4.99 | -- |
| Neurocrine Biosciences Inc | 2.86bn | 478.60m | 13.16bn | 2.00k | 28.12 | 4.04 | 25.87 | 4.60 | 4.66 | 4.66 | 27.91 | 32.50 | 0.6851 | 0.8244 | 4.91 | 1,430,250.00 | 11.46 | 9.00 | 13.48 | 10.78 | 98.18 | 98.32 | 16.73 | 13.51 | 3.30 | -- | 0.00 | -- | 21.45 | 22.29 | 40.23 | 3.28 | 25.55 | -- |
| Viatris Inc | 14.30bn | -3.51bn | 17.14bn | 30.00k | -- | 1.17 | -- | 1.20 | -2.96 | -2.96 | 12.22 | 12.78 | 0.3634 | 2.20 | 5.44 | 476,663.30 | -8.93 | -1.35 | -10.68 | -1.61 | 39.55 | 40.86 | -24.58 | -4.18 | 0.8162 | 2.78 | 0.4948 | -- | -2.98 | 3.66 | -454.23 | -- | -7.35 | -- |
| Incyte Corp | 5.14bn | 1.29bn | 19.52bn | 2.84k | 15.31 | 3.77 | 14.14 | 3.80 | 6.40 | 6.40 | 25.61 | 26.04 | 0.8291 | 4.33 | 5.48 | 1,807,750.00 | 20.75 | 11.34 | 27.83 | 14.38 | 93.26 | 93.92 | 25.03 | 16.48 | 3.25 | -- | 0.0067 | 0.00 | 21.22 | 14.03 | 3,844.96 | -- | -20.67 | -- |
| Moderna Inc | 1.94bn | -2.82bn | 19.68bn | 4.70k | -- | 2.27 | -- | 10.12 | -7.26 | -7.26 | 5.00 | 21.95 | 0.1468 | 4.27 | 7.17 | 413,617.00 | -21.31 | 10.19 | -25.32 | 13.43 | 70.32 | 75.74 | -145.16 | 19.02 | 3.22 | -- | 0.0684 | 0.00 | -39.93 | 19.33 | 20.75 | -- | 24.53 | -- |
| Holder | Shares | % Held |
|---|---|---|
| BlackRock Fund Advisorsas of 31 Dec 2025 | 10.12m | 10.15% |
| The Vanguard Group, Inc.as of 31 Dec 2025 | 8.95m | 8.98% |
| Dodge & Coxas of 31 Dec 2025 | 5.51m | 5.52% |
| JPMorgan Investment Management, Inc.as of 31 Dec 2025 | 4.40m | 4.41% |
| SSgA Funds Management, Inc.as of 31 Dec 2025 | 4.24m | 4.26% |
| AQR Capital Management LLCas of 31 Dec 2025 | 3.27m | 3.28% |
| Renaissance Technologies LLCas of 31 Dec 2025 | 2.24m | 2.25% |
| Geode Capital Management LLCas of 31 Dec 2025 | 2.06m | 2.07% |
| T. Rowe Price Associates, Inc. (IM)as of 31 Dec 2025 | 1.78m | 1.79% |
| Bellevue Asset Management AGas of 31 Dec 2025 | 1.70m | 1.71% |
